What is DEXLEVO?
Founded in 2012, DEXLEVO operates at the intersection of advanced material science and aesthetic medicine. The company specializes in the development of biopolymer-based medical devices designed to enhance skin health and rejuvenation. Unlike traditional fillers, DEXLEVO's core technology focuses on stimulating natural biological responses, positioning the firm as a high-growth player within the competitive medical aesthetics sector. By maintaining a robust R&D pipeline in Seoul, the company has successfully transitioned from a niche developer to a significant supplier of specialized medical products, attracting interest from major institutional investors and financial conglomerates.
How much funding has DEXLEVO raised?
DEXLEVO has raised a total of $22M across 1 funding round:
Other Financing Round
$22M
Other Financing Round (2021): $22M with participation from Magna Investment, HYUNDAI VENTURE INVESTMENT, Shinhan Financial Group, and Smilegate Investment
Key Investors in DEXLEVO
Magna Investment
A private investment firm established in 2005, Magna Investment focuses on sustainable growth through strategic allocations across Real Estate, Private Equity, and Venture Capital.
HYUNDAI VENTURE INVESTMENT
Hyundai Venture Investment Corp is a specialized venture capital and private equity firm based in Seoul, South Korea, focused on identifying high-potential technology enterprises.
Shinhan Financial Group
A comprehensive financial services organization providing global banking, investment, and wealth management solutions with an extensive international footprint.
What's next for DEXLEVO?
With the recent influx of capital, DEXLEVO is expected to prioritize the commercialization of its flagship biopolymer products across key global markets. The strategic roadmap likely includes expanding its distribution network into North America and Europe, where demand for non-invasive aesthetic procedures continues to rise. Furthermore, the company is anticipated to invest heavily in clinical trials to validate the long-term safety and efficacy of its proprietary technology. As DEXLEVO moves into this next phase of enterprise-level growth, the focus will remain on scaling manufacturing capabilities and strengthening its intellectual property portfolio to maintain a competitive edge in the rapidly evolving medical device industry.
See full DEXLEVO company page
